Introduction
============

Acute kidney injury (AKI) is known to increase the mortality rate and prolong hospital stay and healthcare cost \[[@ref1]\]. AKI is common among hospitalized patients, and its incidence has been continuously increasing for several decades \[[@ref1]-[@ref3]\]. Approximately 40% to 60% of patients who are admitted to the intensive care unit develop AKI \[[@ref4],[@ref5]\] and require renal replacement therapy \[[@ref5]-[@ref7]\]. Continuous renal replacement therapy (CRRT) is a widely used renal replacement modality, particularly when patients have AKI and are unstable, because it can easily control biochemical imbalance associated with AKI \[[@ref8],[@ref9]\]. Considering the critical condition of patients with AKI, the accurate prediction of patient prognosis after CRRT has received increasing attention; however, further research is warranted.

Albumin is involved in many physiological responses, such as osmotic pressure maintenance, drug metabolism \[[@ref10]\], immune system regulation \[[@ref11]\], and antioxidant effects \[[@ref10],[@ref12]\]. Thus, hypoalbuminemia reflects several pathological conditions, such as organ failure, nutritional deficiency, and inflammation \[[@ref13],[@ref14]\]. Hypoalbuminemia is identified in up to 30% of hospitalized patients at admission \[[@ref15]\], and it is associated with mortality, prolonged hospital stay, and several complications \[[@ref16]-[@ref18]\]. The mortality rates of patients who present on an emergency basis with hypoalbuminemia are three times higher than the mortality rates of patients with normal albumin levels, despite adjustment for the effects of comorbidities \[[@ref16]\]. Hypoalbuminemia occurs even more frequently in critically ill patients. However, its relationship with short-term and long-term mortality in patients undergoing CRRT remains unclear. Therefore, the present study aimed to assess the effect of hypoalbuminemia on mortality in a large cohort of patients undergoing CRRT.

Methods
=======

Patient and data collection
---------------------------

The study design was approved by the Institutional Review Board of Seoul National University Hospital (approval no. H-1812-069-993) and was conducted in accordance with the principles of the Declaration of Helsinki. The study retrospectively reviewed 2,205 patients who underwent CRRT at Seoul National University Hospital from June 2010 to December 2016. Among them, patients who were under 18 years of age (n = 299) and those who had previously undergone maintenance dialysis for end-stage renal disease (n = 325) were excluded. Finally, 1,581 patients were analyzed in the present study. The need to acquire informed consent from the patients was waived.

We collected the following baseline demographic data: age, sex, weight, AKI cause, dialysis dose, hypertension, diabetes mellitus, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, malignancy, and mechanical ventilation use. The AKI causes were classified into the following four categories: septic, postoperative, nephrotoxic, and other causes. If there appeared to be a direct cause related with surgery and the surgery was performed within 24 hours prior to the initiation of CRRT, the cause was classified as postoperative. Multifactorial AKI was classified according to the main cause. The other causes of AKI included hepatorenal syndrome (n = 46), other ischemic injury (n = 356), sudden cardiac arrest (n = 76), and others (n = 189). Laboratory data included serum creatinine, hemoglobin, sodium, potassium, and albumin levels. The Acute Physiology Assessment and Chronic Health Evaluation II (APACHE II) score was measured at CRRT initiation \[[@ref19]\].

Outcomes
--------

The primary outcome was all-cause mortality after CRRT. This outcome was further stratified according to the timeframe (2 weeks, 1 month, 6 months, and 1 year). With regard to short-term mortality, intensive care unit mortality and in-hospital mortality were also evaluated. The information on all-cause mortality was obtained from the National Database of Statistics Korea.

Statistical analysis
--------------------

Categorical and continuous variables are expressed as proportion and mean ± standard deviation when they were normally distributed and as median with interquartile range when they were not normally distributed, respectively. The normality of the distribution was analyzed using the Kolmogorov-Smirnov test. The chi-square test was used to compare categorical variables. Fisher's exact test was used when the chi-square test was not applicable, and Student t test or the Mann-Whitney U test was used for continuous variables with or without a normal distribution. Nonlinear relationships were explored with a restricted cubic spline analysis. The odds ratios (ORs) and confidence intervals for mortality were calculated using logistic regression analysis. Kaplan-Meier survival curves were drawn and compared using the log-rank test. A Cox proportional hazard regression model was applied to calculate the hazard ratios (HRs) of the risk of mortality. The adjusting variables were as follows: age; sex; weight; AKI cause; target dose; mean arterial pressure; hypertension; diabetes mellitus; history of ischemic heart disease, cerebrovascular disease, and peripheral vascular disease; malignancy; mechanical ventilation; laboratory findings, such as creatinine, hemoglobin, sodium, and potassium levels; and the APACHE II score. All statistical analyses were performed using IBM SPSS Statistics (version 23.0; IBM Corp., Armonk, NY, USA). A P value \< 0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

The mean patient age was 63.2 ± 15.2 years, and 60.5% of the patients were male. The proportion of patients with sepsis was 38.7%. Patients were divided into three groups according to the tertiles of the serum albumin levels, and the serum albumin levels were ≤ 2.4, 2.5 to 2.9, and ≥ 3.0 g/dL from the first to the third tertiles. The AKI cause, dialysis dose, malignancy presence, hemoglobin level, potassium level, and APACHE II score differed among the tertiles. The baseline characteristics are presented in [Table 1](#T1){ref-type="table"}.

Relationship between serum albumin and mortality
------------------------------------------------

During a median follow-up period of 16 days (range, 13-19 days; maximum, 4 years), 1,040 patients (65.8%) died. The mortality incidence was 20.4 deaths per 1,000 person-days. When a nonlinear relationship was applied, the risk of mortality increased as the serum albumin level decreased ([Fig. 1](#F1){ref-type="fig"}). After categorizing the patients into tertiles, a significant gap was noted among the survival curves of the tertiles (*P* \< 0.001 by log-rank test) ([Fig. 2](#F2){ref-type="fig"}). When a Cox regression model was applied, the risk of mortality was higher in the first tertile group than in the third tertile group, and this remained significant despite adjustment for multiple variables ([Table 2](#T2){ref-type="table"}).

Although patients who died within 24 hours of CRRT were excluded (n = 247), the first tertile group remained at risk of mortality when compared with the finding in the third tertile group (adjusted HR, 1.28 \[1.063-1.541\]; *P* = 0.009). When analysis was performed after stratification by the presence of septic AKI, the risk of mortality was higher in the first tertile group than in the third tertile group (adjusted HR, 1.56 \[1.223-1.988\] for septic AKI; adjusted HR, 1.58 \[1.276-1.958\] for non-septic AKI).

When the serum albumin level was considered a continuous variable in the multivariate regression model, the risk of mortality showed a 1.7-fold increase with each 1 g/dL decrease in the serum albumin level. When the analysis was stratified according to the timeframes of follow-up, the risk of mortality was higher in the first tertile group than in the third tertile group (ORs: 2.5 \[1.22-4.99\] for 24-hour mortality, 2.3 \[1.72-3.11\] for 1-week mortality, 1.7 \[1.40--2.53\] for 1-month mortality, and 1.8 \[1.31--2.40\] for 6-month mortality) ([Table 3](#T3){ref-type="table"}). When intensive care unit and in-hospital mortalities were evaluated, patients with high albumin levels had a survival benefit when compared with the findings in those with hypoalbuminemia ([Table 4](#T4){ref-type="table"}).

Discussion
==========

Hypoalbuminemia is associated with increased morbidity and mortality in several pathological conditions. Despite the clinical implications of hypoalbuminemia, its relationship with mortality in patients receiving CRRT has not been demonstrated. To our knowledge, the present study is the first to show that hypoalbuminemia is associated with high mortality after CRRT initiation. This trend was independent of the timeframe of follow-up or the location of death (intensive care unit or hospital ward).

Hypoalbuminemia might result from several pathological conditions, such as malnutrition and inflammation \[[@ref20]\]. These conditions might be associated with impaired immunity, the recurrence of hospital-acquired infection \[[@ref21]\], or an increase in infection-related death \[[@ref22]\]. A hypoalbuminemia-induced inflammatory state has been shown to interfere with proper homeostatic responses in the postoperative period \[[@ref20]\] and affect surgical outcomes \[[@ref23],[@ref24]\]. The patients with hypoalbuminemia in the present study might have had inflammatory or impaired immune milieu before CRRT, with subsequent high mortality.

Albumin has an antioxidant property that defends against oxidative stress \[[@ref12]\]. After ischemic stroke, patients with hypoalbuminemia display a poor prognosis because of impaired neuroprotection against oxidative stress \[[@ref25]\]. In patients with kidney disease, excessive oxidative stress can induce the development and progression of injury \[[@ref26],[@ref27]\]. Thus, patients with hypoalbuminemia are at risk of AKI and chronic kidney disease \[[@ref18],[@ref28]\]. According to these mechanisms, the patients with hypoalbuminemia in the present study might not recover organ function in the long-term, including kidney function, and might have a high risk of mortality.

As hypoalbuminemia has a negative effect on patient prognosis, the use of albumin replacement therapy has been continuously increasing for many years \[[@ref29]\]. The first randomized controlled trial to demonstrate the effect of albumin administration in patients with hypoalbuminemia was the Saline versus Albumin Fluid Evaluation (SAFE) study \[[@ref30]\], which included 7,000 critically ill patients. This study compared the effect of 4% albumin solution with that of normal saline, but there was no difference in 28-day mortality. However, in subgroup analysis, albumin therapy appeared to improve survival in patients with sepsis. A recent sepsis guideline suggests that albumin therapy can be considered in patients with severe sepsis who do not respond to crystalloid infusion \[[@ref31]\]. Nevertheless, another recent study involving patients with sepsis admitted to the intensive care unit did not confirm the survival benefit of albumin infusion \[[@ref32]\]. Although correction of hypoalbuminemia is a clinical issue, the present observational study could not prove the efficacy of albumin replacement in patients receiving CRRT.

The present study has some limitations. In addition to the causal relationship issue, unidentified variables might have had a confounding effect on the relationship. As this was a single-center study, the characteristics of the study patients might have differed from those of patients in other cohorts or patients not undergoing CRRT. Finally, we did not consider whether the change in the albumin level or the replacement of albumin after CRRT was associated with mortality.

In conclusion, the present study addressed the predictive value of hypoalbuminemia with regard to short-term and long-term mortality in patients starting CRRT. Although several factors might be associated with patient outcomes, serum albumin is beneficial in terms of its easy measurement in routine clinical practice. Accordingly, the serum albumin level should be monitored at CRRT initiation, and clinicians should be aware of the negative effects of hypoalbuminemia.
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###### 

Baseline patient characteristics

  Characteristic                      Total (n = 1,581)   Albumin group                                 *P* value                                                   
  ----------------------------------- ------------------- --------------------------------------------- --------------------------------------------- ------------- ----------
  Age (yr)                            63.2 ± 15.2         63.2 ± 15.1                                   63.8 ± 15.1                                   62.6 ± 15.3   0.326
  Male sex (%)                        60.5                61.3                                          61.3                                          59.0          0.681
  Body weight (kg)                    60.5 ± 13.1         60.9 ± 14.1                                   60.7 ± 12.6                                   59.6 ± 12.5   0.135
  Acute kidney injury cause (%)       \< 0.001                                                                                                                      
  Sepsis                              38.7                56.0                                          41.1                                          20.7          
  Surgery                             10.4                7.3                                           8.6                                           14.9          
  Nephrotoxin                         8.7                 5.3                                           8.9                                           11.6          
  Others                              42.2                31.4                                          41.4                                          52.8          
  Hemodiafiltration dose (mL/kg/hr)   42.4 ± 14.0         44.5 ± 15.3[c](#t1fn2){ref-type="table-fn"}   43.2 ± 14.5[c](#t1fn2){ref-type="table-fn"}   39.7 ± 11.5   \< 0.001
  Hypertension (%)                    28.4                26.7                                          30.1                                          28.2          0.470
  Diabetes mellitus (%)               29.0                24.4                                          29.9                                          32.1          0.021
  Ischemic heart disease (%)          12.5                10.6                                          12.0                                          14.6          0.143
  Cerebrovascular disease (%)         12.1                10.6                                          12.2                                          13.5          0.367
  Peripheral vascular disease (%)     7.3                 6.1                                           7.5                                           8.3           0.397
  Malignancy (%)                      36.7                42.8                                          37.6                                          30.4          \< 0.001
  Mechanical ventilation (%)          84.0                87.0                                          82.8                                          82.5          0.096
  Blood tests                                                                                                                                                       
  Creatinine (mg/dL)                  2.7 ± 1.8           2.6 ± 1.7                                     2.8 ± 1.8                                     2.7 ± 1.8     0.392
  Hemoglobin (g/dL)                   9.8 ± 2.2           9.3 ± 2.1[c](#t1fn2){ref-type="table-fn"}     9.7 ± 2.0[c](#t1fn2){ref-type="table-fn"}     10.3 ± 2.2    \< 0.001
  Sodium (mmol/L)                     138.6 ± 7.9         138.8 ± 8.4                                   138.8 ± 7.7                                   138.1 ± 7.7   0.269
  Potassium (mmol/L)                  4.3 ± 0.9           4.4 ± 1.0                                     4.2 ± 0.9[a](#t1fn2){ref-type="table-fn"}     4.3 ± 0.8     0.009
  Albumin (g/dL)                      2.7 ± 0.6           2.1 ± 0.3[c](#t1fn2){ref-type="table-fn"}     2.7 ± 0.1[c](#t1fn2){ref-type="table-fn"}     3.4 ± 0.4     \< 0.001
  APACHE II score                     30.4 ± 9.1          37.5 ± 9.5[a](#t1fn2){ref-type="table-fn"}    35.0 ± 10.1                                   35.4 ± 10.9   \< 0.001
  Follow-up duration (d)              12 (3-32)           5 (1-22)[b](#t1fn2){ref-type="table-fn"}      14 (3-36)                                     16 (5-35)     0.048

APACHE, Acute Physiology and Chronic Health Evaluation.

*P* \< 0.05; ^b^*P* \< 0.01; ^c^*P* \< 0.001 (compared with the third tertile group).

###### 

Hazard ratios of all-cause mortality according to the serum albumin levels

  Albumin group    Range (g/dL)   Events (%)   Univariate           Multivariate[a](#t2fn2){ref-type="table-fn"}                        
  ---------------- -------------- ------------ -------------------- ---------------------------------------------- -------------------- ----------
  Third tertile    ≥ 3.0          56.6         1 (Reference)                                                       1 (Reference)        
  Second tertile   2.5-2.9        55.8         1.19 (1.020-1.386)   0.027                                          1.06 (0.904-1.242)   0.472
  First tertile    ≤ 2.4          70.7         1.90 (1.634-2.209)   \< 0.001                                       1.57 (1.332-1.842)   \< 0.001

APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; HR, hazard ratio.

Adjusted for age; sex; weight; acute kidney injury cause; target dose; mean arterial pressure; hypertension; diabetes mellitus; history of ischemic heart disease, cerebrovascular disease, and peripheral vascular disease; malignancy; mechanical ventilation; laboratory findings, such as creatinine, hemoglobin, sodium, and potassium levels; and APACHE II score.

###### 

Odds ratios ratios of cumulative mortality at different timeframes according to the serum albumin levels

  Timeframe        Albumin group   Events (%)           Univariate      Multivariate[a](#t3fn2){ref-type="table-fn"}                   
  ---------------- --------------- -------------------- --------------- ---------------------------------------------- --------------- --
  24 hours         Third tertile   7.5                  1 (Reference)                                                  1 (Reference)   
  Second tertile   13.5            2.07 (1.373-3.122)   0.001           2.04 (1.015-4.133)                             0.045           
  First tertile    27.4            5.03 (3.424-7.389)   \< 0.001        2.46 (1.216-4.992)                             0.012           
  1 week           Third tertile   28.2                 1 (Reference)                                                  1 (Reference)   
  Second tertile   35.2            1.38 (1.070-1.786)   0.013           1.19 (0.896-1.580)                             0.230           
  First tertile    55.8            3.21 (2.480-4.156)   \< 0.001        2.31 (1.715-3.105)                             \< 0.001        
  1 month          Third tertile   45.7                 1 (Reference)                                                  1 (Reference)   
  Second tertile   54.3            1.46 (1.150-1.845)   0.002           1.12 (0.939-1.603)                             0.134           
  First tertile    69.2            2.73 (2.116-3.515)   \< 0.001        1.70 (1.402-2.532)                             \< 0.001        
  6 months         Third tertile   55.0                 1 (Reference)                                                  1 (Reference)   
  Second tertile   63.1            1.44 (1.136-1.836)   0.003           1.18 (0.898-1.537)                             0.241           
  First tertile    76.4            2.71 (2.075-3.532)   \< 0.001        1.77 (1.305-2.401)                             \< 0.001        

APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; OR, odds ratio.

Adjusted for age; sex; weight; acute kidney injury cause; target dose; mean arterial pressure; hypertension; diabetes mellitus; history of ischemic heart disease, cerebrovascular disease, and peripheral vascular disease; malignancy; mechanical ventilation; laboratory findings, such as creatinine, hemoglobin, sodium, and potassium levels; and APACHE II score.

###### 

Odds ratios of intensive care unit mortality and in-hospital mortality according to the serum albumin levels

                          Albumin group        Univariate      Multivariate[a](#t4fn2){ref-type="table-fn"}                   
  ----------------------- -------------------- --------------- ---------------------------------------------- --------------- --
  ICU mortality           Third tertile        1 (Reference)                                                  1 (Reference)   
  Second tertile          1.29 (1.019-1.641)   0.035           1.11 (0.846-1.442)                             0.464           
  First tertile           2.51 (1.942-3.251)   \< 0.001        1.77 (1.315-2.374)                             \< 0.001        
  In-hospital mortality   Third tertile        1 (Reference)                                                  1 (Reference)   
  Second tertile          1.37 (1.077-1.750)   0.011           1.13 (0.858-1.479)                             0.390           
  First tertile           2.67 (2.037-3.498)   \< 0.001        1.77 (1.299-2.413)                             \< 0.001        

APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; ICU, intensive care unit; OR, odds ratio.

Adjusted for age; sex; weight; acute kidney injury cause; target dose; mean arterial pressure; hypertension; diabetes mellitus; history of ischemic heart disease, cerebrovascular disease, and peripheral vascular disease; malignancy; mechanical ventilation; laboratory findings, such as creatinine, hemoglobin, sodium, and potassium levels; and APACHE II score.
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